Bharat Parenterals Receives 'Hold' Rating Upgrade

Bharat Parenterals, a microcap pharmaceutical company, has recently received a 'Hold' rating from MarketsMOJO on December 4, 2023. This upgrade is based on the company's strong ability to service debt, with a low Debt to EBITDA ratio of 1.02 times. The stock is currently in a bullish range, with technical indicators such as MACD, Bollinger Band, and KST showing positive trends. However, the company's ROCE of 6.2 indicates a fair valuation with an Enterprise value to Capital Employed ratio of 1.5. Despite generating a return of 56.53% in the past year, which is significantly higher than the market (BSE 500) returns of 16.72%, Bharat Parenterals has seen a decline in profits by -0.5%. The majority shareholders of the company are the promoters. While the short-term performance of the stock has been impressive, the company's long-term growth has been poor. Over the last 5 years, the net sales have only grown at an annual rate of 1.03%, and the operating profit at 4.16%. In the latest quarter, the company has declared negative results after two consecutive positive quarters. The net sales have fallen by -26.97%, and the PBT LESS OI has fallen by -73.75%. Despite these challenges, Bharat Parenterals remains a promising player in the pharmaceutical industry, with a strong ability to service debt and a bullish technical trend.